Sight Sciences, Inc. (SGHT) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Sight Sciences, Inc. (SGHT) Q1 2026 Earnings Call Transcript
Sight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance
Sight Sciences to Present at Two Upcoming Investor Conferences
Sight Sciences Announces the Release of its Sustainability Report
Sight Sciences Announces the Release of its Sustainability Report
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
Insider Selling: Sight Sciences (NASDAQ:SGHT) EVP Sells $10,615.30 in Stock
Sight Sciences (NASDAQ:SGHT) CTO Sells $28,424.64 in Stock
Paul Badawi Sells 29,244 Shares of Sight Sciences (NASDAQ:SGHT) Stock
Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Americana Partners LLC Grows Stock Holdings in Sight Sciences, Inc. $SGHT
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
What Makes Sight Sciences, Inc. (SGHT) a Strong Momentum Stock: Buy Now?
Sight Sciences (SGHT) Upgraded to Buy: Here's What You Should Know
Sight Sciences, Inc. (SGHT) Q3 2025 Earnings Call Transcript
Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer
Sight Sciences to Present at Two Upcoming Investor Conferences
Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
SGHT Shares Rise on Meta-Analysis Showing OMNI's Long-Term Benefits
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
Sight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments
Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
Sight Sciences, Inc. (SGHT) Q2 2025 Earnings Call Transcript
Compared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key Metrics
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th
Sight Sciences, Inc. (SGHT) Q1 2025 Earnings Call Transcript